Relmada Operating Cycle from 2010 to 2026
| RLMD Stock | USD 3.88 0.28 7.78% |
Operating Cycle | First Reported 2010-12-31 | Previous Quarter 362.83 | Current Value 344.69 | Quarterly Volatility 26.1 K |
Check Relmada Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Relmada Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 101.3 M, Selling General Administrative of 45.5 M or Selling And Marketing Expenses of 16.3 M, as well as many indicators such as Price To Sales Ratio of 4.1 K, Dividend Yield of 0.0 or PTB Ratio of 0.48. Relmada financial statements analysis is a perfect complement when working with Relmada Therapeutics Valuation or Volatility modules.
Relmada | Operating Cycle | Build AI portfolio with Relmada Stock |
Analyzing Relmada Therapeutics's Operating Cycle over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Operating Cycle has evolved provides context for assessing Relmada Therapeutics's current valuation and future prospects.
Latest Relmada Therapeutics' Operating Cycle Growth Pattern
Below is the plot of the Operating Cycle of Relmada Therapeutics over the last few years. It is Relmada Therapeutics' Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Relmada Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Operating Cycle | 10 Years Trend |
|
Operating Cycle |
| Timeline |
Relmada Operating Cycle Regression Statistics
| Arithmetic Mean | 21,716 | |
| Geometric Mean | 3,637 | |
| Coefficient Of Variation | 120.38 | |
| Mean Deviation | 24,524 | |
| Median | 2,023 | |
| Standard Deviation | 26,141 | |
| Sample Variance | 683.4M | |
| Range | 59K | |
| R-Value | (0.79) | |
| Mean Square Error | 278.2M | |
| R-Squared | 0.62 | |
| Significance | 0.0002 | |
| Slope | (4,071) | |
| Total Sum of Squares | 10.9B |
Relmada Operating Cycle History
About Relmada Therapeutics Financial Statements
Relmada Therapeutics stakeholders use historical fundamental indicators, such as Relmada Therapeutics' Operating Cycle, to determine how well the company is positioned to perform in the future. Although Relmada Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Relmada Therapeutics' assets and liabilities are reflected in the revenues and expenses on Relmada Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Relmada Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Operating Cycle | 362.83 | 344.69 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Relmada Therapeutics is a strong investment it is important to analyze Relmada Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Relmada Therapeutics' future performance. For an informed investment choice regarding Relmada Stock, refer to the following important reports:Check out the analysis of Relmada Therapeutics Correlation against competitors. For information on how to trade Relmada Stock refer to our How to Trade Relmada Stock guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Will Pharmaceuticals sector continue expanding? Could Relmada diversify its offerings? Factors like these will boost the valuation of Relmada Therapeutics. Anticipated expansion of Relmada directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Relmada Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Relmada Therapeutics's market price often diverges from its book value, the accounting figure shown on Relmada's balance sheet. Smart investors calculate Relmada Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Relmada Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Relmada Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Relmada Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Relmada Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.